SY SYK Stryker Corporation Loading... : Bullish and Bearish Analyst Opinions

Revvity's AI strategy is based on the belief that AI-generated discoveries will create a 'demand bottleneck' for physical validation, requiring more wet lab tools and reagents, positioning them to benefit from the build-out of AI infrastructure in life sciences. — This thesis implies a secular tailwind for lab tools companies as AI accelerates the number of drug targets, potentially benefiting peers like Danaher (DHR) and Thermo Fisher (TMO).